|Day Low/High||170.90 / 175.73|
|52 Wk Low/High||147.60 / 270.63|
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.
The Swiss biotech was last year reported to be a target of Shire.
Company to expand into 500 Kendall Street and create a 550,000-square-foot campus focused on rare diseases and highly specialized conditions
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.
The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.
Stocks slip on Tuesday in a weaker start to November as uncertainty over the upcoming presidential election weighs on Wall Street.
Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.
Wall Street suffered a dismal start to the month on Tuesday as conflicting polls bred uncertainty over the upcoming presidential election.
Stocks extend losses by mid-afternoon Tuesday in a weaker start to November as uncertainty over the upcoming presidential election weighs on Wall Street.
The German DAX leads the way as all major European indices close in the red on Tuesday.
The Federal Reserve will again convene in the coming week to discuss monetary policy, but investors will instead focus on what it may mean for a rate hike in December.
Data support progressing with Phase 3 clinical development program
PharmaEngine Eligible to Receive US$25 Million of Milestone Payment
Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.
-- Results from the National Eye C.A.R.E. Survey reinforce potential link between tech-dependency and growing risk of dry eye disease
Given the biotech's growth prospects and pipeline assets, its shares seem greatly undervalued.